| abstract |
"new amanitin conjugate". The invention relates to a conjugate comprising (a) an amatoxine comprising (i) an amino acid 4 with a 6'-deoxy position; and (ii) an amino acid 8 with an s-deoxy position; (b) a bcma linking group comprising (i) the variable domains of the humanized j22.9-isy antibody, and (ii) a heavy chain constant region comprising a d265c mutation; and (c) a binder that binds amatoxine and said target binding group; furthermore, the invention relates to a pharmaceutical composition comprising such a conjugate, particularly for use in the treatment of multiple myeloma. |